Topiramate treatment of sexual addiction

Primary Psychiatry

Volumn 12, Issue 11, 2005, Pages 31-32

  Ginsberg, David L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; CARBONATE DEHYDRATASE; FLUOXETINE; GLUTAMATE RECEPTOR; KAINIC ACID RECEPTOR; NALTREXONE; TOPIRAMATE; VOLTAGE GATED SODIUM CHANNEL;

ADULT; BEHAVIOR THERAPY; CASE REPORT; COGNITIVE THERAPY; COMPULSION; DIZZINESS; GROUP THERAPY; GUILT; HUMAN; MALE; MICTURITION DISORDER; REVIEW; SEXUAL ADDICTION; SEXUAL DYSFUNCTION;

EID: 28544434773     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Goodman A. Diagnosis and treatment of sexual addiction. J Sex Marital Ther. 1993;19:225-251.
2. Grant JE, Kim SW. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann Clin Psychiatry. 2001;13:229-231.
3. Coleman E, Gratzer T, Nesvacil L, et al. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. J Clin Psychiatry. 2000;61:282-284.
4. Nishimura H, Suzuki M, Kasahara H, et al. Efficacy of lithium carbonate on public and compulsive masturbation: a female case with mild mental disability. Psychiatry Clin Neurosci. 1997;51:411-413.
5. Kafka MP, Prentky R. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry. 1992;53:351-358.
6. Kafka M. Current concepts in the drug treatment of paraphilias and paraphilia-related disorders. CNS Drugs. 1995;3:9-12.
7. Balfour ME, Yu L, Coolen LM. Sexual behavior and sex-associated environmental cues activate the mesolimbic system in male rats. Neuropsychopharmacology. 2004;29:718-730.
8. Bradford JM. The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behavior. Can J Psychiatry. 2001;46:26-34.
9. Markind JE. Topiramate: a new antiepileptic drug. Am J Health-Syst Pharm. 1998;55:554-562.
10. Van Ameringen MV, Mancini C, Pipe B, et al. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry. 2002;63:981-984.
11. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss (letter). Can J Psychiatry. 2000;45:198.
12. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with open-label topiramate: a clinical case series. J Clin Psychiatry. 2000;61:368-372.
13. Knable MB. Topiramate for bulimia nervosa in epilepsy (letter). Am J Psychiatry. 2001;158:322-323.
14. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary study. J Clin Psychiatry. 2002;63:15-20.
15. Weber MVK. Topiramate for obstructive sleep apnea and snoring (letter). Am J Psychiatry. 2002;159:872-873.
16. Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1221-1223.
17. Cheseaux M, Monnat M, Zullino DF. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol. 2003;18:375-377.
18. Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clinical Neuropharmacology. 2003;26:1-4.
19. Komanduri R. Two cases of alcohol craving curbed by topiramate (letter). J Clin Psychiatry. 2003;64:612.
20. Shapira NA, Lessig MC, Murphy TK, et al. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. 2002;5:141-145.
21. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495-499.
22. Shapira NA, Lessig M, Murphy TK, et al. Evaluation of open-label topiramate for scar therapy. Dermatol Online. 2003;9:3.
23. Fong TW, De La Garza II R, Newton TF. A case report of topiramate in the treatment of nonparaphilic sexual addiction (letter). J Clin Psychopharmacol. 2005;25:512-514.
24. Topamax (package insert). Ortho-McNeil Pharmaceutical, Inc., December 2003.
25. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):S18-22.
26. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol. 2001;119:1210-1211.
27. Klufas A, Thompson D. Topiramate-induced depression (letter). Am J Psychiatry. 2001;158:1736.